Overview

Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy

Status:
Recruiting

Trial end date:
2022-12-20

Target enrollment:

Participant gender:

Summary

FASTERCC: Folic acid supplement versus placebo for treating mucositis adverse events in metastatic renal cell carcinoma patients receiving targeted therapy. A randomized, double-blind trial from the Danish renal cancer group (DARENCA study-4)

Phase:

Phase 2

Details

Lead Sponsor:

Frede Donskov

Treatments:

Folic Acid
Vitamin B Complex